Subgroup analyses.

<p><b>A</b>. Hazard ratios of myocardial infarction (MI) in specific subgroups of sulfonylureas treated patients by using insulin as reference group. <b>B</b>. Hazard ratios of MI in specific subgroups of meglitinides treated patients by using insulin as reference group. <b>C</b>. Hazard ratios of MI in specific subgroups of TZD treated patients by using insulin as reference group. Abbreviations: CI, confidence interval; CVD, cardiovascular disease (combination of coronary artery disease, ischemic stroke, hemorrhagic stroke, peripheral artery disease); CHF, congestive heart failure; HTN, hypertension; HR, hazard ratio; TZD, thiazolidinedione.</p

Patient flow diagram.

<p>Patient flow diagram.</p

Incidence of acute coronary syndrome by prescriptions.

<p>Incidence of acute coronary syndrome by prescriptions.</p

Adjusted hazard ratios (95% CI) of developing myocardial infarction in patients receiving sulfonylurea, meglitinides or TZD with insulin treatment as the reference and subgroup analyses.

<p>Adjusted hazard ratios (95% CI) of developing myocardial infarction in patients receiving sulfonylurea, meglitinides or TZD with insulin treatment as the reference and subgroup analyses.</p

Kaplan–Meier curves showing the development of myocardial infarction (MI) among patients with Insulin (black), sulfonylureas (red), meglitinides (green) and TZD (blue).

<p>The log-rank analysis showed significant different (P < 0.001). Abbreviation: TZD, thiazolidinedione.</p

Demographic and clinical characteristics of study subjects.

<p>Demographic and clinical characteristics of study subjects.</p

Linear and nonlinear heart rate variability parameters of the study subjects in mortality and survival groups.

<p>Linear and nonlinear heart rate variability parameters of the study subjects in mortality and survival groups.</p

Cumulative incidence curve for total mortality according to the contribution of DFAα1 using competing risk model.

<p>The survival significant decreased if the DFAα1 was below 0.95.</p

Basic characteristics of the study subjects in mortality and survival groups.

<p>Basic characteristics of the study subjects in mortality and survival groups.</p

Cox’s regression model by using HRV parameters as predictors for cardiac mortality and total mortality.

<p>Cox’s regression model by using HRV parameters as predictors for cardiac mortality and total mortality.</p